166 related articles for article (PubMed ID: 29430310)
1. Morphological Transformation of Myeloma Cells into Multilobated Plasma Cell Nuclei within 7 Days in a Case of Secondary Plasma Cell Leukemia That Finally Transformed as Anaplastic Myeloma.
Fujimi A; Nagamachi Y; Yamauchi N; Kanisawa Y
Case Rep Hematol; 2017; 2017():5758368. PubMed ID: 29430310
[TBL] [Abstract][Full Text] [Related]
2. A case of aggressive multiple myeloma with cleaved, multilobated, and monocytoid nuclei, and no serum monoclonal gammopathy.
Yeh YA; Pappas AA; Flick JT; Butch AW
Ann Clin Lab Sci; 2000 Jul; 30(3):283-8. PubMed ID: 10945569
[TBL] [Abstract][Full Text] [Related]
3. Secondary plasma cell leukemia.
Rotaru I; Găman G; Dumitrescu D; Foarfă C
Rom J Morphol Embryol; 2012; 53(4):1073-6. PubMed ID: 23303035
[TBL] [Abstract][Full Text] [Related]
4. Fine-needle aspiration cytology of a case of HIV-associated anaplastic myeloma.
Stewart JM; Krishnamurthy S
Diagn Cytopathol; 2002 Oct; 27(4):218-22. PubMed ID: 12357499
[TBL] [Abstract][Full Text] [Related]
5. Leukaemic Transformation of Multiple Myeloma in Post Chemotherapy Remission Phase.
Agarwal P; Nayak P; Singh PA; Mishra BK
J Clin Diagn Res; 2016 Apr; 10(4):ED23-4. PubMed ID: 27190822
[TBL] [Abstract][Full Text] [Related]
6. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
Huang WR; Li R; Jing Y; Zhang YZ; Wu XX; Gao CJ; Bo J; Yu L; Wang QS; Da WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1146-50. PubMed ID: 17204182
[TBL] [Abstract][Full Text] [Related]
7. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
9. Secondary Plasma Cell Leukemia in a Recurrent Multiple Myeloma: Rare Case Scenario.
Inamdar AA; Loo A; Mikhail N; Lee P
Cureus; 2020 Jun; 12(6):e8456. PubMed ID: 32642366
[TBL] [Abstract][Full Text] [Related]
10. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
[TBL] [Abstract][Full Text] [Related]
11. Aggressive primary plasma cell leukemia with skin manifestations, trisomy 8 and molecular oligoclonal features.
Robak T; Urbańska-Rys H; Robak E; Bartkowiak J; Strzelecka B; Biernat W; Kordek R
Leuk Lymphoma; 2002 May; 43(5):1067-73. PubMed ID: 12148888
[TBL] [Abstract][Full Text] [Related]
12. Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment.
Brück P; Mousset S; Bühme A; Hoelzer D; Atta J
Int J Hematol; 2007 Jul; 86(1):66-8. PubMed ID: 17675269
[TBL] [Abstract][Full Text] [Related]
13. Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature.
Sekiguchi Y; Ichikawa K; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2015; 8(8):9609-19. PubMed ID: 26464727
[TBL] [Abstract][Full Text] [Related]
14. Acquired del(9)(p22.3) in a primary plasma cell leukemia.
Achkar WA; Wafa A; Aljapawe A; Othman MA; Alhourani E; Liehr T
Mol Cytogenet; 2013 Aug; 6(1):33. PubMed ID: 23985162
[TBL] [Abstract][Full Text] [Related]
15. Plasma Cell Leukaemia: A Rare Yet Aggressive Plasma Cell Dyscrasia With A Very Poor Response To Conventional Therapy.
Khan N; Raza SS; Khan UI; Hafez I; Abdullah MA; Hassan M; Rukh Hijaz AS; Hussain AK; Nadeem MD
J Ayub Med Coll Abbottabad; 2019; 31(2):272-275. PubMed ID: 31094130
[TBL] [Abstract][Full Text] [Related]
16. Plasma cell myeloma with cleaved, multilobated, and monocytoid nuclei.
Zukerberg LR; Ferry JA; Conlon M; Harris NL
Am J Clin Pathol; 1990 May; 93(5):657-61. PubMed ID: 2183587
[TBL] [Abstract][Full Text] [Related]
17. Plasma cell leukemia: from biology to treatment.
Jelinek T; Kryukov F; Rihova L; Hajek R
Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
[TBL] [Abstract][Full Text] [Related]
18. Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
Krüger WH; Kiefer T; Schüler F; Lotze C; Busemann C; Dölken G
Onkologie; 2007 Apr; 30(4):193-5. PubMed ID: 17396042
[TBL] [Abstract][Full Text] [Related]
19. Xanthoma-like Skin Changes in an Elderly Woman with a Normal Lipid Profile.
Nockowski P; Woźniak Z; Reich A; Maj J
Acta Dermatovenerol Croat; 2017 Jul; 25(2):167-169. PubMed ID: 28871936
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
